Tengion is a leader in the field of regenerative medicine. We are using a patient's own cells to develop products that regenerate, repair or replace diseased and dysfunctional human organs and tissues.

Video: Tengion Neo-Urinary Conduit™

Watch as the Neo-Urinary Conduit development process is described for use in patients with bladder cancer.

* IE users only: You may be redirected to upgrade
security components and install an Active X control.

The video you are linking to depicts experimental technology invented by, and procedures performed at, Children's Hospital Boston. This technology serves as the foundation for Tengion's lead product candidate, the Neo-Bladder Augment, which is currently in Phase 2 clinical trials. Tengion's Neo-Bladder Augment is investigational and has not been approved by the FDA for commercial sale. Additionally, the Neo-Bladder Augment may not be appropriate for all patients and medical results depicted in this video may not be experienced by others using this technology.

Tengion Provides Business Update and Reports First Quarter 2013 Financial Results May 15, 2013

Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden April 1, 2013

Tengion Provides Business Update and Reports Fourth Quarter and Full Year 2012 Financial Results March 18, 2013

Tengion to Present at 25th Annual ROTH Conference March 12, 2013

Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013 March 11, 2013

Tengion is a leader in the field of regenerative medicine. We are using a patient's own cells to develop products that regenerate, repair or replace diseased and dysfunctional human organs and tissues.

All News »